BMO Study Says Doctors Don't Like Valeant / Allergan Merger - Hedge Fund Alpha (formerly ValueWalk Premium)
Allergan Valeant

BMO Study Says Doctors Don't Like Valeant / Allergan Merger

As behind the scenes negotiations to purchase Allergan, Inc. (NYSE:AGN) are ongoing – and ValueWalk sources who had been providing a steady stream of behind the scenes information take a more circumspect tone – comes a Bank of Montreal analysis that supports Allergan’s claims that they have won the important hearts and minds of doctors. Valeant and Allergan fighting to win support of ophthalmologists Doctors and more specifically ophthalmologists are a key influencer in the decision making process to purchase Allergan’s products. As reported in The Wall Street Journal, both Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and Allergan, Inc. (NYSE:AGN)...

This content is exclusively for paying members of Hedge Fund Alpha

Gain Exclusive Access to the Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Get Started Now with a FREE 7-Day Trial🔻

If you are a current Hedge Fund Alpha member and are having an account error please clear cache and cookies. If that does not work, email [email protected] or click Chat.

Saved Articles